VM4 Stock Overview A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Vanda Pharmaceuticals Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Vanda Pharmaceuticals Historical stock prices Current Share Price US$4.40 52 Week High US$6.10 52 Week Low US$3.18 Beta 0.76 1 Month Change -10.57% 3 Month Change 3.29% 1 Year Change n/a 3 Year Change -71.97% 5 Year Change -70.47% Change since IPO -42.86%
Recent News & Updates
Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024 Nov 08
Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024 Nov 07
Vanda Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31 Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million. Oct 14
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis Sep 19
Vanda Pharmaceuticals Inc. Reinstates Financial Guidance for the Full Year 2024 Aug 01 See more updates
Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024 Nov 08
Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024 Nov 07
Vanda Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31 Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million. Oct 14
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis Sep 19
Vanda Pharmaceuticals Inc. Reinstates Financial Guidance for the Full Year 2024 Aug 01
Vanda Pharmaceuticals Inc. to Report Q2, 2024 Results on Jul 31, 2024 Jul 26 Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc. (NYSE:BLK), Butler Hall Capital LLC, Shareholder Capital LLC and others. Jun 27
Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA). Jun 20
Cycle Pharmaceuticals Limited made a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) for approximately $490 million. Jun 08
Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc. (NYSE:BLK), Butler Hall Capital LLC, Shareholder Capital LLC and others. May 26
Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness May 16
First quarter 2024 earnings released: US$0.072 loss per share (vs US$0.057 profit in 1Q 2023) May 09 Vanda Pharmaceuticals Inc. to Report Q1, 2024 Results on May 08, 2024 Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others. Apr 19
Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million. Apr 17
Vanda Pharmaceuticals' Fanapt (Iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder Apr 03
Insider recently sold €68k worth of stock Mar 07
Vanda Pharmaceuticals Announces FDA Update for Supplemental NDA for HETLIOZ in the Treatment of Insomnia Mar 06
New minor risk - Profit margin trend Feb 08
Full year 2023 earnings released: EPS: US$0.044 (vs US$0.11 in FY 2022) Feb 08
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia Feb 07
Now 23% undervalued after recent price drop Feb 07
Vanda Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 07, 2024 Feb 01
Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Approval for VTR-297 for the Treatment of Onychomycosis Jan 31
Vanda Pharmaceuticals Inc. Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S Jan 23
Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis Dec 05
Investor sentiment deteriorates as stock falls 19% Nov 16
Third quarter 2023 earnings released: EPS: US$0.002 (vs US$0.058 in 3Q 2022) Nov 09
Vanda Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023 Nov 02
Investor sentiment deteriorates as stock falls 17% Sep 07
Investor sentiment deteriorates as stock falls 15% Aug 04
Second quarter 2023 earnings released: EPS: US$0.026 (vs US$0.046 in 2Q 2022) Jul 28
Vanda Pharmaceuticals Inc. to Report Q2, 2023 Results on Jul 27, 2023 Jul 23
Senior VP recently sold €89k worth of stock Jun 19
Vanda Pharmaceuticals Inc Reports Results from a Phase III study of Tradipitant in Motion Sickness May 26
Vanda Pharmaceuticals Inc. Responds to the Ruling in its Hetlioz(R) Abbreviated New Drug Application Appeal May 12
First quarter 2023 earnings released: EPS: US$0.057 (vs US$0.12 loss in 1Q 2022) May 06
Insider recently sold €99k worth of stock Mar 08
Insufficient new directors Mar 01
Full year 2022 earnings released: EPS: US$0.11 (vs US$0.60 in FY 2021) Feb 10
Vanda Pharmaceuticals Inc. to Report Q4, 2022 Results on Feb 08, 2023 Feb 02
Vanda Pharmaceuticals Inc. Announces Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study Dec 20
Senior VP recently sold €53k worth of stock Dec 19
Vanda Pharmaceuticals Provides an Update to HETLIOZ ANDA Litigation Appeal: Federal Circuit Grants Motion to Temporarily Enjoin Generic Launch Dec 18
Investor sentiment deteriorated over the past week Dec 14
Now 22% undervalued Dec 13
Vvanda Pharmaceuticals Inc. Reports Results in A Phase II Clinical Study of Vqw-765 in the Treatment of Acute Performance Anxiety Dec 03
Third quarter 2022 earnings released: EPS: US$0.058 (vs US$0.14 in 3Q 2021) Nov 04
Vanda Pharmaceuticals Inc. Revises Financial Guidance for the Year 2022 Nov 03
Vanda Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 27
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Vanda Pharmaceuticals Inc. Securities Litigation Oct 08
Vanda Pharmaceuticals Inc. Announces Notice of Opportunity for an FDA Hearing on the sNDA for HETLIOZ in Jet Lag Disorder Sep 08 Shareholder Returns VM4 DE Biotechs DE Market 7D 1.9% -3.5% -2.0% 1Y n/a -14.7% 6.9%
See full shareholder returns
Return vs Market: Insufficient data to determine how VM4 performed against the German Market .
Price Volatility Is VM4's price volatile compared to industry and market? VM4 volatility VM4 Average Weekly Movement 8.6% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: VM4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: VM4's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia.
Show more Vanda Pharmaceuticals Inc. Fundamentals Summary How do Vanda Pharmaceuticals's earnings and revenue compare to its market cap? VM4 fundamental statistics Market cap €267.12m Earnings (TTM ) -€15.71m Revenue (TTM ) €182.92m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) VM4 income statement (TTM ) Revenue US$190.86m Cost of Revenue US$12.18m Gross Profit US$178.67m Other Expenses US$195.06m Earnings -US$16.39m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 08:23 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Vanda Pharmaceuticals Inc. is covered by 21 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Difei Yang Aegis Capital Corporation null null Argus Research Company Olivia Brayer BofA Global Research
Show 18 more analysts 
